Free Trial
NASDAQ:ENSC

Ensysce Biosciences Q1 2025 Earnings Report

Ensysce Biosciences logo
$2.41 +0.07 (+2.99%)
Closing price 03:58 PM Eastern
Extended Trading
$2.40 -0.01 (-0.21%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences EPS Results

Actual EPS
-$1.39
Consensus EPS
-$3.02
Beat/Miss
Beat by +$1.63
One Year Ago EPS
N/A

Ensysce Biosciences Revenue Results

Actual Revenue
$1.32 million
Expected Revenue
$0.65 million
Beat/Miss
Beat by +$670.00 thousand
YoY Revenue Growth
N/A

Ensysce Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Ensysce Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ensysce Biosciences Earnings Headlines

Ensysce Flat on Receiving Grant
Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Ensysce Biosciences secures patent for OUD treatment
See More Ensysce Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email.

About Ensysce Biosciences

Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

View Ensysce Biosciences Profile

More Earnings Resources from MarketBeat